5TQ7 image
Entry Detail
PDB ID:
5TQ7
Title:
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2016-10-23
Release Date:
2017-01-11
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.28
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase JAK2
Mutations:M1073S, F1076T, I1126V
Chain IDs:A, B
Chain Length:304
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
Primary Citation
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.
J. Med. Chem. 60 767 786 (2017)
PMID: 27983835 DOI: 10.1021/acs.jmedchem.6b01634

Abstact

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures